Elsilimomab
Alternative Names: BE-8Latest Information Update: 16 Aug 2017
At a glance
- Originator OPi
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Multiple myeloma; Post-transplant lymphoproliferative disorder
Most Recent Events
- 16 Aug 2017 Discontinued - Phase-I/II for Lymphoma in France (unspecified route)
- 16 Aug 2017 Discontinued - Phase-II for Multiple myeloma in France (unspecified route)
- 16 Aug 2017 Discontinued - Phase-II for Post-transplant lymphoproliferative disorder in France (unspecified route)